Hemostemix Inc.

TSXV:HEM Stock Report

Market Cap: CA$16.0m

Hemostemix Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSXV:HEM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Oct 25BuyCA$175,002Thomas SmeenkIndividual3,500,000CA$0.05
18 Aug 25BuyCA$19,500Summerhill Investment CorpCompany260,000CA$0.075
11 Aug 25BuyCA$45,085Summerhill Investment CorpCompany600,000CA$0.075
05 Aug 25BuyCA$23,000Thomas SmeenkIndividual200,000CA$0.12
23 Jul 25BuyCA$1,499,997Summerhill Investment CorpCompany15,000,000CA$0.10
25 Mar 25BuyCA$10,732Thomas SmeenkIndividual100,000CA$0.11
06 Mar 25BuyCA$48,523Summerhill Investment CorpCompany319,500CA$0.16
03 Mar 25BuyCA$860,877Summerhill Investment CorpCompany5,380,500CA$0.16
03 Mar 25SellCA$884,996Peter LaceyIndividual5,900,000CA$0.15
03 Mar 25BuyCA$512,538Peter LaceyIndividual3,416,937CA$0.15
03 Mar 25SellCA$512,538Peter LaceyIndividual3,416,937CA$0.15
28 Feb 25SellCA$64,411Peter LaceyIndividual376,222CA$0.18
26 Feb 25BuyCA$35,000Summerhill Investment CorpCompany200,000CA$0.18
24 Feb 25SellCA$24,600Summerhill Investment CorpCompany150,000CA$0.16

Insider Trading Volume

Insider Buying: HEM insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HEM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders19,252,69110.2%
Private Companies21,760,00011.5%
General Public147,475,85078.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52%.

Top Shareholders

Top 5 shareholders own 21.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.5%
Summerhill Investment Corp
21,760,000CA$1.8m269%no data
4.05%
Thomas Smeenk
7,643,052CA$649.7k84.5%no data
4.05%
Loran Swanberg
7,626,445CA$648.2k64.8%no data
1.81%
Peter Lacey
3,416,937CA$290.4k0%no data
0.3%
Ronnie Hershman
566,257CA$48.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 12:37
End of Day Share Price 2025/11/21 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.